Executives
-
Dorbin John W. Jr.General Counsel -
Cohen SethCFO
-
Versi EbrahimCEO
-
Moss Ronald B.Chief Medical Officer
-
Marguglio David J.SVP and Chief Business Officer
-
Carlo Dennis J PhdPresident & CEO
-
Benedicto David C.Chief Financial Officer
-
Hopkins Robert OChief Financial Officer
-
Daniels Karen K.VP of Operations
?
Hopkins Robert O
Chief Financial Officer
Adamis Pharmaceuticals Corporation
US, San Diego [HQ]
CIK
1461736
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
289,810
Price per Share :
$0.78
Equivalence :
$226,051.80
Transaction History
-
S289,810 Shares After TransactionValue : $118,822.10Sold $2,963.89Transaction Date : 11/18/20
-
Footnotes
-
-
Footnotes:#1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.#2 The shares were sold to satisfy the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person.#3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4025 to $0.408, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.#4 Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.
-
S294,781 Shares After TransactionValue : $256,459.47Sold $6,453.66Transaction Date : 08/18/20
-
Footnotes
-
-
Footnotes:#1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.#2 The shares were sold to satisfy the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person.#3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.956, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.#4 Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.
-
S254,810 Shares After TransactionValue : $104,472.10Sold $14,350.00Transaction Date : 11/20/20
-
Footnotes
-
-
Footnotes:#1 The sales reported in this Form 4 were for the sole purpose of satisfying or paying income or withholding tax obligations of the undersigned.#2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4028 to $0.4076, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
-
M254,809 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/21/20
-
Footnotes
-
-
Footnotes:#1 Represents the vesting of a portion of previously granted restricted stock units (RSU), with shares of common stock to be issued following vesting of the RSUs as described in the award agreement relating to the RSUs.#2 Includes common stock, as well as restricted stock units granted on January 30, 2019, to the reporting person and previously reported on a Form 4.
-
M277,067 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/21/21
-
Footnotes
-
-
Footnotes:#1 Represents the vesting of a portion of previously granted restricted stock units (RSU), with shares of common stock to be issued following vesting of the RSUs as described in the award agreement relating to the RSUs.#2 Includes common stock, as well as restricted stock units granted on January 30, 2019, to the reporting person and previously reported on a Form 4.